

**DOCUMENT NUMBER:** 

**DOCUMENT TITLE:** 

**DOCUMENT NOTES:** 

LOCATION:

VERSION:

DOC TYPE:

STATUS:

**EFFECTIVE DATE:** 

NEXT REVIEW DATE:

**RELEASE DATE:** 

**EXPIRATION DATE:** 

**AUTHOR:** 

**PREVIOUS NUMBER:** 

**OWNER:** 

**CHANGE NUMBER:** 

# Fecal Occult Blood Using Beckman Coulter Card

Purpose	This CLIA-waived procedure is to establish guidelines for performing fecal occult blood testing on feces at point-of-care using the Beckman Coulter Card, and to provide the patient early detection of abnormal bleeding associated with gastrointestinal disorders.
Scope	This procedure may be performed by personnel who are trained and approved to perform POCT as defined in Chapter 510 of the California Business and Professional Code (CBPC) or per departmental policy (e.g., RN, LVN, CRNA, PA, DO, MD, CNM, & RNP) whichever is more restrictive
Policy	<ul> <li>Fecal Occult Blood Test will be performed for screening purposes.</li> <li>Staff must be tested and evaluated for visual color discrimination and may not perform this test if the employee is unable to discriminate colors produced by this test.</li> <li>Based on the results of the Beckman Coulter Card test, the provider will determine whether a more definitive or laboratory test should be ordered.</li> <li>Testing reagents and slide cards are not to be interchanged between each kit or with components from any other manufacturer.</li> <li>Only testing on feces may be performed at point of care.</li> <li>External Quality Control (QC) checks should be performed in checking function and stability of Beckman Coulter Cards prior to use for each new lot number and/or shipment of kits.</li> <li>Performance Monitor (Quality Control) will be done and recorded with each patient test.</li> <li>If the Performance Monitor (Quality Control) does not perform as expected, the test will be repeated with another slide test card. If the Performance Monitor (Quality Control) still fails, the local laboratory Point of Care Coordinator will be contacted. Patient results will not be reported. Patient specimens will be sent to the local laboratory.</li> <li>Remedial action will be documented when expected Performance Monitor (Quality Control) results are not obtained.</li> </ul>
Specimen source	Fecal specimen
	Continued on next page

Specimen collection	<ul> <li>digital</li> <li>Specim (e.g. Pa glass c</li> <li>The test</li> </ul>	pecimen should be collected preferably from bowel movement. A rectal exam may be performed but it is not recommended. Then containers should be labeled with two unique patient identifiers atient Name and Medical Record Number) in a clean dry plastic or ontainer if collected from a bowel movement. St requires only a small fecal specimen. The specimen is applied to the Beckman Coulter Card as a thin smear.
Reagents and materials	stored . • E N a • E S N u • Comm for che • Clock o	eckman Coulter Cards test consists of two main components that are at a controlled room temperature $(15^{\circ}\text{C}-30^{\circ}\text{C})$ : Beckman Coulter Cards (Test Cards) containing guaiac paper. Note: Protect slides from heat, light, and volatile chemicals (e.g., mmonia, bleach, bromine, iodine, household cleaners). Beckman Coulter Developer – a developing solution containing a tabilized mixture in an aqueous solution. Note: Protect from heat and the bottle kept tightly capped when not in ise. It is flammable and subject to evaporation. ercial Controls or Diluted Whole Blood (1:5000 in distilled water) cking function and stability of Beckman Coulter Cards. or timer e collection cups
Safety	Refer to precaution	safety manual for general safety requirements and universal ons.
Function and stability checks	Follow th	nese steps to perform function and stability checks.
-	Step	Action
	1	Perform function and stability checks using commercial controls
		or diluted whole blood (1:5000 in distilled water).
	2	Verify the lot number and expiration date indicated on the commercial control bottle or diluted whole blood (1:5000 in distilled water).
	3	Mix well and apply a drop in Box A and apply another drop in Box B.

Function and stability checks (continued)

Step	Action		
4	Close cover and wait 3-5 minutes after sample application before		
	developing test.		
5	• On the develop test, open flap and apply two (2) drops of		
	Beckman Coulter developer over each smear.		
	• Interpret within 60 seconds.		
	If	Then	
	There is a presence of any	Result as POSITIVE.	
	trace of detectable blue color		
	on or at the edge of the smear		
	There is no detectable blue	Result as NEGATIVE.	
	color on or at the edge of the		
	smear		
	Performance Monitor	• Test is not valid.	
	Controls fail to appear and/or	• Do not report patient	
	background interferes with	results.	
	reading	• Follow procedure block	
		Troubleshooting Failed Controls.	
6	<ul> <li>6 • On the Develop Performance Monitor areas, apply one drop Beckman Coulter developer between the (+) and (-) Perform Monitor Areas.</li> <li>• Interpret within 10 seconds.</li> </ul>		
	If	Then	
	Positive Performance Monitor	Positive Performance Monitor	
	Area is blue	is OK.	
	Negative Performance	Negative Performance	
	Monitor Area is colorless	Monitor is OK.	
	Internal Controls fail to	• Test is not valid.	
	appear and/or background	• Follow procedure block	
	interferes with reading	<b>Troubleshooting Failed</b>	
		Controls.	

 Troubleshooting failed controls
 Follow these corrective action steps to troubleshoot failed controls.

 Step
 Action

Step	Action
1	Repeat the test using another card.
2	Repeat the test using a new kit.
3	• If control results are still out of range, contact the local laboratory Point of Care Coordinator.
	<ul> <li>Do <u>NOT</u> perform patient testing until the problem is resolved.</li> <li>Send patient specimens to the local laboratory.</li> </ul>

Testing patient sample		
	Step	Action
	1	Make a positive patient identification using two unique identifiers

Ste	p Action
1	Make a positive patient identification using two unique identifiers
	(patient name and MRN) prior to testing a patient's stool sample.
2	Collect a small stool sample and apply a thin smear in Box A and
	apply another thin smear in Box B.
3	Close cover and wait 3-5 minutes after sample application before
	developing test.

## Testing patient sample (continued)

Step	Action		
4	<ul> <li>On the develop test, open flap and apply two (2) drops of Beckman Coulter developer over each smear.</li> <li>Interpret within 60 seconds.</li> </ul>		
	If	Then	
	There is a presence of any trace of detectable blue color on or at the edge of the smear	Result as POSITIVE.	
	There is no detectable blue color on or at the edge of the smear	Result as NEGATIVE.	
	Performance Monitor	• Test is not valid.	
	Controls fail to appear and/or background	<ul> <li>Do <u>not</u> report patient results.</li> <li>Send patient specimens to the</li> </ul>	
	interferes with reading	<ul> <li>local laboratory.</li> <li>Repeat with new specimen and/or a new Test Card. If the control fails to appear on repeat test, contact the local laboratory Point of Care Coordinator.</li> </ul>	

#### Testing patient sample (continued)


Step		Action
5		
	If	Then
	Positive Performance Monitor Area is blue	Positive Performance Monitor Control is <b>OK</b> .
	Negative Performance Monitor Area is colorless	Negative Performance Monitor Control <b>is OK.</b>
	Performance Monitor Controls fail to appear and/or background interferes with reading	<ul> <li>Test is not valid.</li> <li>Do <u>not</u> report patient results</li> <li>Send patient specimens to the local laboratory.</li> <li>Repeat with new specimen and/or a new Test Card. If the control fails to appear on repeat test,</li> </ul>
		contact the local laboratory Point of Care Coordinator.
6	Document results directly int Patient Logs/Forms.	o KP HealthConnect or use Manual

Expected results

Patient Test: Negative

- In a general screening population of highly compliant asymptomatic individuals, a positivity rate of approximately 3% was obtained; among a similar group of less compliant individuals, a positivity rate of about 7% was observed. The false-positivity rate for colorectal disease was 1 to 3% depending on the population studied.
- Positivity rates for fecal occult blood tests have been shown to vary in each patient population depending on diet, age, predisposition to colorectal disease, and other factors that may be associated with bleeding gastrointestinal lesions.

Limitations of procedure	<ul> <li>Bowel lesions, including some polyps and colorectal cancers, may not bleed at all or may bleed intermittently. Also, blood, if present, may not be distributed uniformly in the fecal specimen. Consequently, a test result may be negative even when disease is present.</li> <li>Conversely, a Beckman Coulter Card test result may be positive on</li> </ul>
	specimens from healthy patients. This may be due to interfering substances in the diet or to medications. It may also be due to low but detectable levels of blood loss, common to both healthy adults and patients with gastrointestinal disease.
	<ul> <li>Therefore, as with any occult blood test, results with the Beckman Coulter Card test cannot be considered conclusive evidence of the presence or absence of gastrointestinal bleeding or pathology. Beckman Coulter Card <i>tests</i> are designed for preliminary screening as an aid to diagnosis. They are not intended to replace other diagnostic procedures such as sigmoidoscopy, colonoscopy, barium enema, or other x-ray studies.</li> </ul>
	<ul> <li>The Beckman Coulter Card test, as well as other unmodified fecal occult blood tests, should not be used to test gastric specimens. Interfering factors, such as low pH, high drug concentrations, metal ions or plant peroxidase in food, may affect the function of guaiac-based occult blood tests. Gastroccult®, available from Beckman Coulter Primary Care Diagnostics, is specifically designed to detect occult blood in gastric specimens.</li> <li>Addition of a drop of water (rehydration) to the guaiac test card prior to the</li> </ul>
	addition of the developer increases the sensitivity of the test, but also increases the number of false-positive test results. For this reason, <b>rehydration is not a recommended procedure</b> for the Beckman Coulter Card test.



## Quick Reference of Beckman Coulter Card

A. Identification Using a ball-point pen. write patient name,

#### B. Preparing the Test

- Using applicator provided, collect small fecal sample.
- Apply thin smear covering Box A.
   Reuse applicator to obtain second sample from a different part of feces. Apply thin smear covering
- Box B.
   Close cover flap. Dispose of applicator in waste container.
- C. Developing the Test
   Slides are best developed no sooner than three days after sample application to allow for degradation of any fruit and vegetable peroxidases that may be present in the fecal sample. However, if immediate testing is required, wait 3 to 5 minutes before developing.
- Open back of slide and apply two drops of Hemoccult<sup>®</sup>SENSA<sup>®</sup> Developer to guaiac paper directly over each smear.
- Read results within 60 seconds. Any trace of blue on or at the edge of the smear is positive for occult blood.
- D. Developing the Performance Monitor<sup>®</sup> Feature (Quality Control)
- The Performance Monitor<sup>®</sup> areas must be developed on every slide.
- Apply one drop of Hemoccult<sup>®</sup> SENSA<sup>®</sup> Developer between the positive and negative Performance Monitor<sup>®</sup> areas.
- Read results within 10 seconds.
   If the slide and developer are functional, a blue color will appear in the positive Performance Monitor\* area and no blue will appear in the negative Performance Monitor\* area.
- Neither the intensity nor the shade of the blue from the Positive Performance Monitor\* area should be used as a reference for the appearance of positive test results.
- Any blue originating from the positive Performance Monitor<sup>®</sup> area should be ignored when reading the sample test results.

Non-Controlled documents	The following non-controlled documents support this procedure.
	<ul> <li>TJC, CAMH, Waived Testing, 2013.</li> <li>College of American Pathologists, Point-of-Care Testing Checklist, July 29, 2013.</li> <li>Commission on Office Laboratory Accreditation (COLA) Criteria.</li> <li>Beckman Coulter FOBT Test Product Insert</li> <li>BIO-RAD Quantify Control Package Insert</li> </ul>
Controlled documents	The following controlled document supports this procedure. Regional Parent Document Reference Number: SCPMG-PPP-0179 Rev. 01
	Reference           Regional Point-of-Care Quality Assurance Program

### Reviewed and approved by:

Signature	Date
alk-	10/23/14
li Yeon Kim, MD, MPH CLIA Laboratory Director SCPMG Target Laboratories	
CLIA Laboratory Director SCPMG Target Laboratories	

Reviewed and approved by (for Medical Center Area Approval Only):

SIGNATURE	DATE
Name: Operations Director, Area Laboratory	
operations Director, Area Laboratory	
Name:	
CLIA Laboratory Director	

# **HISTORY PAGE**

Type of Change: New Major, Minor	Description of Change(s)	Quality Systems Leader/Date	Operations Director, Area Laboratory Review/Date	CLIA Laboratory Director Review/Date	Date Change Implemented